NMSC

Epredia and NovaScan Announce Intent to Enter U.S. Distribution Agreement for MarginScan™ Device for Non-Melanoma Skin Cancer Detection

Retrieved on: 
星期五, 五月 3, 2024
Biotechnology, Health, General Health, Pharmaceutical, Oncology, Other Science, Medical Devices, Research, Hospitals, Surgery, Science, MMS, Sale, Cancer, Partnership, Skin cancer, NMSC, Patient, Physician, Multimedia, Marketing, Neoplasm, Letter, Medical imaging

View the full release here: https://www.businesswire.com/news/home/20240502185446/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240502185446/en/
    MarginScan™ Device for Non-Melanoma Skin Cancer Detection (Photo: Business Wire)
    Skin cancer is the most common group of cancers diagnosed worldwide1, and it is estimated that one in five Americans will develop skin cancer in their lifetime2.
  • Non-melanoma skin cancers (NMSC) are the most common cancers in the United States, affecting more than 3 million Americans a year3.
  • Most surgeries for NMSC are simple excisions, which may result in removal of substantial healthy tissue around the suspected cancer.
  • With this planned agreement, Epredia will serve as the primary distribution partner of MarginScan™ and will have exclusive distribution rights in the United States.

Dermatology Association of Radiation Therapy (DART) Opposes Move to Cancel Medicare Coverage for Nonsurgical Treatment of Nonmelanoma Skin Cancer in Seven States

Retrieved on: 
星期一, 四月 29, 2024
Education, Keloid, LCD, American Academy, Radiation, NCCN, Mohs surgery, Carcinoma, Policy, Skin, DART, National Comprehensive Cancer Network, American Academy of Dermatology, Recurrence, Research, SCC, Comment, Doctor of Philosophy, SRT, Radiation therapy, Documentation, NMSC, Patient, Treatment, Society, AAD, RT, BCC, ASTRO, Health insurance

The proposed LCD at issue, DL39808 " Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC) ," would affect residents in North and South Carolina, Virginia, West Virginia, Alabama, Georgia and Tennessee.

Key Points: 
  • The proposed LCD at issue, DL39808 " Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC) ," would affect residents in North and South Carolina, Virginia, West Virginia, Alabama, Georgia and Tennessee.
  • The DART filing noted, "In its current form, the LCD is fundamentally misdirected, misguided, and inappropriate.
  • It would altogether remove any semblance of patient choice or physician clinical decision making for patients who are diagnosed with NMSC.
  • At the outset, DART underscores that the proposed LCD was filed as a Medicare Part A policy.

FOX News Media Names Diana Jachman and Nathaniel King as Recipients of Fifth Annual Dr. Charles Krauthammer Memorial Scholarship

Retrieved on: 
星期三, 五月 1, 2024
Other Entertainment, TV and Radio, Other Education, General Entertainment, University, Primary, Secondary, Education, Entertainment, Theta, Fox News, National Merit Scholarship Program, Weather, Fox, Utah State University, Fox Business, National Honor Society, Psychiatry, FBN, Fox Nation, Physics, Hospital, Pulitzer, National Magazine Awards, Midtown High School, Economics, News, The Weekly Standard, Breaking news, Commonwealth, FNC, Fox Corporation, Partnership, The Washington Post, Prosper High School, Unipolar, Knowledge, ENG, Culture Club, NMSC, Television, Balliol College, Oxford, Journalism, Harvard Medical School, Pulitzer Prize, Multimedia, Special, PSAT/NMSQT, Fox Weather, McGill University, Bradley Foundation

FOX News Media, in partnership with the National Merit Scholarship Program, has selected Diana Jachman and Nathaniel King as the recipients of its fifth annual Dr. Charles Krauthammer Memorial Scholarship, announced FOX News Media CEO Suzanne Scott.

Key Points: 
  • FOX News Media, in partnership with the National Merit Scholarship Program, has selected Diana Jachman and Nathaniel King as the recipients of its fifth annual Dr. Charles Krauthammer Memorial Scholarship, announced FOX News Media CEO Suzanne Scott.
  • Jachman is the daughter of FOX News Channel’s (FNC) Atlanta bureau ENG field photographer Thomas Jachman, and King is the son of FNC’s Dallas bureau ENG field photographer Scott King.
  • In making the announcement, Scott said, “We are pleased to name Diana and Nathaniel as the recipients of the fifth annual Dr. Charles Krauthammer Memorial Scholarship.
  • FOX News Media operates the FOX News Channel (FNC), FOX Business Network (FBN), FOX News Digital, FOX News Audio, FOX News Books, the direct-to-consumer streaming services FOX Nation and FOX News International and the free ad-supported television service FOX Weather.

SkinCure Oncology Unveils New Skin Cancer Treatment Technology at American Academy of Dermatology Annual Meeting in San Diego March 8-12 Booth 3555

Retrieved on: 
星期四, 三月 7, 2024
Mohs surgery, Cancer, Carcinoma, SRT, Research, Pathology, FDA, Ageing, Food, RCM, Dermatology, Bed, Physiology, Epidermis, Vision, AAD, NMSC, Skin cancer, PAI, Patent, Patient, Tanning, United, American Academy, Medical imaging

GentleView™ is a laser-based imaging device being developed to offer hybrid reflective confocal microscopy and photoacoustic imaging.

Key Points: 
  • GentleView™ is a laser-based imaging device being developed to offer hybrid reflective confocal microscopy and photoacoustic imaging.
  • Reflective confocal microscopy, or RCM, will provide high resolution imaging of the epidermis, to a depth of 200 microns, for cellular level visualization of skin cancer lesions.
  • “SkinCure Oncology,” Brandt continued, “is helping dermatologists nationwide implement the GentleCure Experience – an advanced, noninvasive treatment for NMSC.
  • “Our new devices, subject to FDA Clearance,” Brandt said, “will offer cutting-edge technology in line with SkinCure Oncology’s vision for the future of dermatology.

SkinCure Oncology Unveils New Skin Cancer Treatment Technology at American Academy of Dermatology Annual Meeting in San Diego March 8-12 Booth 3555

Retrieved on: 
星期四, 三月 7, 2024
Mohs surgery, Cancer, Carcinoma, SRT, Research, Pathology, FDA, Ageing, Food, RCM, Dermatology, Bed, Physiology, Epidermis, Vision, AAD, NMSC, Skin cancer, PAI, Patent, Patient, Tanning, American Academy, Medical imaging

Reflective confocal microscopy, or RCM, will provide high resolution imaging of the epidermis, to a depth of 200 microns, for cellular level visualization of skin cancer lesions.

Key Points: 
  • Reflective confocal microscopy, or RCM, will provide high resolution imaging of the epidermis, to a depth of 200 microns, for cellular level visualization of skin cancer lesions.
  • Brandt noted, "Mohs micrographic surgery has been the gold standard of care for the treatment of nonmelanoma skin cancer (NMSC) for more than 50 years.
  • "SkinCure Oncology," Brandt continued, "is helping dermatologists nationwide implement the GentleCure Experience – an advanced, noninvasive treatment for NMSC.
  • The new devices will feature technology for which SkinCure Oncology was recently awarded U.S. patent coverage.

Medical Journal: Image-Guided Superficial Radiation Therapy Is Superior to Superficial Radiation Therapy Without Guidance

Retrieved on: 
星期二, 二月 20, 2024
Mohs surgery, Skin cancer, Freedom, Recurrence, Carcinoma, Toxicity, SRT, American Academy of Dermatology, Research, ASTRO, FDA, Skin, BCC, Radiation, SCC, NMSC, Society, Silverman, Patient, Histology, Photon, Radiation therapy, Cancer, American Academy, Medical imaging

BURR RIDGE, Ill., Feb. 20, 2024 /PRNewswire/ -- SkinCure Oncology, the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT or IGSRT) for the treatment of nonmelanoma skin cancer, presented to dermatology patients as the GentleCure™ experience, announced the publication of research, "Image guidance improves freedom from recurrence in superficial radiation therapy for non-melanoma skin cancer," in Advances in Radiation Oncology, a peer-reviewed journal from the American Society for Radiation Oncology (ASTRO).

Key Points: 
  • It shows definitively that the new technology is superior, and represents a seminal moment in the care of skin cancer patients using radiation.
  • This study is the first to rigorously compare SRT to IGSRT, and it covers all the data that exists on IGSRT.
  • Superficial radiation therapy was developed over 100 years ago ( here ) and was the standard therapy for nonmelanoma skin cancer until Mohs micrographic surgery emerged in the 1930's ( here ).
  • IGSRT and the GentleCure experience will be showcased at the upcoming American Academy of Dermatology annual meeting in San Diego, at booth 3555.

Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
星期四, 二月 8, 2024
Carcinoma, Neoplasm, Melanoma, NMSC, Merkel-cell carcinoma, REPL, Angiosarcoma, SITC, PFS, Clinical trial, Research, RECIST, Society, Hercules, Patient, CSCC, Type, FDA, Marketing, Investment, RP1, Food, MCC, Immunotherapy, Skin, Nivolumab, Uveal melanoma, Annual general meeting, BLA, RP2, Pharmaceutical industry

WOBURN, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December 31, 2023, and provided a business update.

Key Points: 
  • WOBURN, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December 31, 2023, and provided a business update.
  • We plan to submit a BLA for the treatment of patients with anti-PD1 failed melanoma in 2H 2024.
  • Selling, general and administrative expenses included $4.5 million in stock-based compensation expenses for the third quarter ended December 31, 2023.
  • Net Loss: Net loss was $51.1 million for the third quarter ended December 31, 2023, as compared to a net loss of $39.7 million for the third quarter ended December 31, 2022.

Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers

Retrieved on: 
星期二, 十二月 5, 2023
Chills, CRS, Melanoma, RP1, CRC, Food, Melanoma Research, RECIST, NMSC, Transplant, Diarrhea, FDA, Cytokine release syndrome, Colorectal cancer, SCCHN, Type, RP3, CRR, Fatigue, Headache, Nausea, Itch, Myocarditis, Incidence, Nivolumab, Influenza-like illness, Research, Clinical trial, Injection site reaction, Myalgia, CSCC, Skin cancer, HCC, Weakness, Society, Head, Appetite, RP2, Regeneron Pharmaceuticals, Carcinoma, Investment, Webcast, Patient, Lipase, Angiosarcoma, MCC, Vomiting, Neck, Uveal melanoma, Rash, BLA, Pharmaceutical industry

The CERPASS study was conducted under a Master Clinical Trial Collaboration and Supply Agreement with Regeneron Pharmaceuticals.

Key Points: 
  • The CERPASS study was conducted under a Master Clinical Trial Collaboration and Supply Agreement with Regeneron Pharmaceuticals.
  • The ORR was comparable between the two study groups (52.5% for RP1 plus cemiplimab vs. 51.4% for cemiplimab alone, p=0.692).
  • The registration directed anti-PD1 failed melanoma cohort from the IGNYTE clinical trial includes 140 patients and completed enrollment earlier this year.
  • RP1 monotherapy was well tolerated, and the safety profile was similar to that observed in non-immunocompromised patients with advanced skin cancers.

Broadstreet Names Chris Rakers to Lead Fast-growing Fund Administration Business

Retrieved on: 
星期二, 十二月 12, 2023
Consulting, Data Management, Banking, Accounting, Technology, Professional Services, Philanthropy, Other Philanthropy, Asset Management, Fund Raising, Finance, LISC, Organization, Creativity, Local Initiatives Support Corporation, Health, NMTC, Growth, NMSC, Service, Management, Renewable energy, Northern Trust, Rakers, Thanos Petsos, Broadstreet's

Broadstreet Impact Services has named a seasoned fund solutions executive to lead its fund administration team as part of a multi-year strategy to continue the firm’s significant growth.

Key Points: 
  • Broadstreet Impact Services has named a seasoned fund solutions executive to lead its fund administration team as part of a multi-year strategy to continue the firm’s significant growth.
  • This week, Chris Rakers joined Broadstreet as managing director of fund administration following almost two decades leading tech-enabled fund operations for alternative investment managers.
  • He also served in various roles at Custom House Fund Services, including as chief operating officer, leading a global fund administration team across the US, Europe, and Asia.
  • “We are excited to add Chris’ remarkable range of fund administration experience to our existing impact investing expertise,” said Kevin Boes, CEO of Broadstreet.

Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
星期二, 十一月 7, 2023
Bevacizumab, Patient, FDA, Research, Carboplatin, RP1, NMSC, Biologics license application, Nivolumab, Biotechnology, Financial management, Carcinoma, Cisplatin, Data collection, Disclosure, SITC, Immunotherapy, 8th Plenary Session of the Central Committee of the League of Communists of Serbia, Initiation, RP3, Clinical trial, Marketing, Melanoma, Skin, Annual general meeting, RP2, PTC, CFO, Roche, Society, CSCC, PTC Therapeutics, Therapy, Investment, Calendar, BLA, D, Merkel-cell carcinoma, Pharmaceutical industry, Nursing, Cryptocurrency

WOBURN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced financial results for the fiscal second quarter ended September 30, 2023 and provided a business update.

Key Points: 
  • R&D Expenses: Research and development expenses were $49.1 million for the second quarter ended September 30, 2023, as compared to $28.8 million for the second quarter ended September 30, 2022.
  • S,G&A Expenses: Selling, general and administrative expenses were $14.7 million for the second quarter ended September 30, 2023, as compared to $12.7 million for the second quarter ended September 30, 2022.
  • Selling, general and administrative expenses included $4.7 million in stock-based compensation expenses for the second quarter ended September 30, 2023.
  • Net Loss: Net loss was $60.0 million for the second quarter ended September 30, 2023, as compared to a net loss of $43.1 million for the second quarter ended September 30, 2022.